Endocrine cell carcinomas of the colon and rectum: a clinicopathological evaluation

Komatsubara, Toshihide; Koinuma, Koji; Miyakura, Yasuyuki; Horie, Hisanaga; Morimoto, Mitsuaki; Ito, Homare; Lefor, Alan Kawarai; Sata, Naohiro; Fukushima, Noriyoshi

doi:10.1007/s12328-015-0623-6

Cited by 34 publications

(42 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most colonic NEN (85%) are PDNEC, which contain a non-neuroendocrine component in 25-40% of cases [21,[65][66][67][68] . The latter is usually an adenocarcinoma, but adenoma or squamous-cell carcinoma is found in about 45-65, 30-35%, and 5% of cases, respectively, mostly arising from the mucosa, while the neuroendocrine component frequently develops from deeper layer of the colon wall and may be missed when no further resection of the primary tumour is performed following biopsies.…”

Section: Colon and Rectummentioning

confidence: 99%

“…Surgical resection of localized pancreatic MiNEN containing acinar-cell carcinoma might improve survival [50,63,66] . The potential benefit of adjuvant treatments following resection of localized MiNEN is still undefined, although some retrospective data have suggested a favourable effect [24,30,38,39,68,85] .…”

Section: High-grade Minenmentioning

confidence: 99%

“…Like in high-grade MiNEN, curative-intent resection of localized disease should be proposed whenever possible, followed by adjuvant chemotherapy depending on the pathological factors of relapse [61,63,68,84] . In case of metastases, primary tumour resection can be discussed, when symptomatic, following organ-specific cancer guidelines (mainly for colorectal neoplasms).…”

Section: Intermediate-grade Minenmentioning

confidence: 99%

See 2 more Smart Citations

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms

Cros²,

et al. 2017

View full text Add to dashboard Cite

Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) are a heterogeneous subgroup of rare neoplasms that represent about a third of all poorly differentiated neuroendocrine carcinomas (PDNEC). MiNEN combine a neuroendocrine component, usually a PDNEC, and a non-neuroendocrine component, generally an adenocarcinoma, both accounting for at least 30% of the neoplasm. MiNEN are classified as high-, intermediate-, or low-grade malignancies depending on the metastatic potential of the tumour components. High-grade malignant component should be considered even if it represents <30% of the tumour. The prognosis of MiNEN is generally intermediate between those of the two “pure” components composing it. The aim of this comprehensive review of the literature is to suggest a standardized management of MiNEN. An increasing body of evidence suggests that PDNEC components share molecular abnormalities with their adenocarcinoma counterparts, but also display additional alterations. This advocates for a common origin, and that the presence of a PDNEC component in an adenocarcinoma could indicate a turning point in carcinogenesis.

show abstract

Section: Colon and Rectummentioning

confidence: 99%

Section: High-grade Minenmentioning

confidence: 99%

Section: Intermediate-grade Minenmentioning

confidence: 99%

See 1 more Smart Citation

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms

Cros²,

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The National Comprehensive Cancer Network recommends the use of cisplatin or carboplatin and etoposide (10,11). Currently, prognosis remains poor, with a median survival of 7 to 10 months (12).…”

Section: Discussionmentioning

confidence: 99%

A Rare Type of Colorectal Cancer: Mixed Adeno-Neuroendocrine Carcinoma (MANEC)

Cherbanyk¹,

Gassend²,

Dimitrief³

et al. 2017

chr

View full text Add to dashboard Cite

RezumatScopul acestei lucrări este de a raporta datele clinico-patologice aferente unui caz de adenocarcinom neuroendocrin mixt metastatic (MANEC) cecal; mai puţin de zece astfel de cazuri au fost descrise în literatura de specialitate britanică. Un pacient în vârstă de 57 de ani s-a prezentat cu un adenocarcinom neuroendocrin mixt metastatic (MANEC) cecal cu determinări secundare hepatice şi carcinomatoză peritoneală. S-au efectuat hemicolectomie dreaptă şi omentectomie de urgenţă, urmate de mai multe cicluri de chimioterapie paliativă cu rezultate slabe. Progresia metastatică a continuat, iar pacientul a decedat la 10 luni de la prezentarea la Camera de Gardă. MANEC sunt definite ca formaţiuni alcătuite din minimum 30% componentă neuroendocrină şi minimum 30% din cea adenocarcinomatoasă. Localizarea tumorii, precum şi proporţiile şi comportamentul celor două componente ale sale influenţează tratamentul. Totuşi, ghidurile de chimioterapie rămân slab definite, iar prognosticul rămâne unul sumbru, cu supravieţuirea medie sub un an de zile. AbstractThe aim of this paper is to report the clinicopathological data of one case of mixed metastatic adenoneuroendocrine carcinoma (MANEC) in the caecum; less than ten cases of which have been described in the English literature. A 57-year-old male patient presented with a mixed adenoneuroendocrine carcinoma (MANEC) of the caecum with liver metastasis and peritoneal carcinomatosis. An emergency right hemicolectomy and omentectomy were performed, followed by several cycles of unsuccessful palliative chemotherapy. The metastasis developed further, and the patient died 10 months after presenting to the emergency room. MANECs are defined as containing at least 30% of both a neuroendocrine and an adenocarcinomatous component. The location of the tumour and the proportions and behaviour of its two components influence the treatment. However, chemotherapy guidelines remain poorly defined, and prognosis remains sombre, with median survival of less than one year.

show abstract

“…The introduction of platinum-oriented adjuvant treatment or radiation for neuroendocrine carcinoma was based on the use of these regimens for small cell lung carcinoma, which shows a histological similarity to small cell neuroendocrine carcinoma. In addition, an efficacy of adjuvant chemoradiotherapy for large cell neuroendocrine carcinoma was also reported [49] ; therefore, these regimens should also be candidates regardless of the MANEC subtype [39,50] , though substantial evidence on their efficacy is lacking because most of them have been reported in case series studies.…”

Section: Adjuvant Treatmentmentioning

confidence: 99%

Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma

Tanaka¹,

Kaneko²,

Nozawa³

et al. 2017

Neuroendocrinology

View full text Add to dashboard Cite

Colorectal mixed adenoneuroendocrine carcinoma (MANEC), which acts like an aggressive tumor, is a rare clinical manifestation on which only a limited amount of literature exists. Surgical resection by regional lymphadenectomy is considered as the only curative treatment for colorectal MANEC, and adjuvant chemotherapy or radiotherapy is recommended because of its high recurrence rate. Colorectal MANEC is frequently diagnosed at an advanced stage, when it is unresectable, and chemotherapy plays a central role in its treatment. Pathological confirmation of the target lesion component is critical for regimen selection. If the lesion comprises an adenocarcinomatous component, a regimen for colorectal adenocarcinoma should be administered. For lesions comprising mainly a neuroendocrine carcinomatous component, cisplatin combined with etoposide or irinotecan has proven to be clinically appropriate. Everolimus, a mechanistic target of rapamycin pathway inhibitor, also improves survival. Sunitinib malate, another molecular targeting agent, is effective for treating neuroendocrine carcinoma; however, the evidence on its effectiveness for treating gastrointestinal neuroendocrine carcinoma is insufficient.

show abstract

Endocrine cell carcinomas of the colon and rectum: a clinicopathological evaluation

Abstract: Most endocrine cell carcinomas of the colon and rectum reviewed were MANECs. Though their prognosis was generally poor, chemotherapy may be effective in some patients.

Cited by 34 publications

References 22 publications

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms

A Rare Type of Colorectal Cancer: Mixed Adeno-Neuroendocrine Carcinoma (MANEC)

Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma

Contact Info

Product

Resources

About